Shanmugam Muthusamy's Form 4 filing
Ani Pharmaceuticals Inc (ANIP) · filed Aug 16, 2023
- Accession no.
- 0001870913-23-000003
- Filed
- Aug 16, 2023
- Trade date
- Aug 14-15, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $3.07M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Shanmugam MuthusamyCIK 0001870913 | Director, Officer (HEAD OF R&D, COO-NOVITIUM OPS) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $60.12 to $62.58, inclusive.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $60.81 to $62.59, inclusive.
Referenced by the price of 1 transaction in Table I.